NEW YORK – In documents filed with the US Securities and Exchange Commission on Wednesday, Cue Health said that it is implementing a new cost reduction plan that will result in layoffs of 230 employees, or 49 percent of its workforce.

纽约——在周三提交给美国证券交易委员会的文件中，Cue Health表示，它正在实施一项新的成本削减计划，将导致230名员工或49%的员工被解雇。

The firm implemented the new cost reduction plan after a review of its business and operating expenses, Cue said in the filing. The plan is intended to reduce Cue's cost structure and improve its operational efficiency.

Cue在文件中表示，该公司在对其业务和运营费用进行审查后，实施了新的成本削减计划。该计划旨在降低Cue的成本结构并提高其运营效率。

Cue has implemented several other cost reduction plans, including in January 2023, April 2023, and January 2024 that resulted in layoffs of more than 800 people in total.

Cue还实施了其他几项成本削减计划，包括2023年1月、2023年4月和2024年1月，共裁员800多人。

In March, Cue CEO, Chairman, and President Ayub Khattak stepped down from the company as it began a comprehensive review of its business and operations. Last year, the firm's shareholders expressed concerns about the strategic direction of the company and its business plan, leading to the appointment of a new board member in February. .

3月，Cue首席执行官、董事长兼总裁阿尤布·哈塔克（AyubKhattak）辞去公司职务，开始全面审查其业务和运营情况。去年，该公司的股东对公司的战略方向和经营计划表示担忧，导致2月份任命了一名新的董事会成员。。

Cue has also faced difficulties with the US Food and Drug Administration: the agency denied its request for de novo authorization of its respiratory syncytial virus molecular test for over-the-counter use last month and declined to grant Emergency Use Authorization for its combination COVID-19 and influenza test in January. .

Cue还面临着美国食品和药物管理局的困难：该机构上月拒绝了其呼吸道合胞病毒分子检测非处方使用的从头授权请求，并拒绝批准其1月份的新型冠状病毒和流感联合检测的紧急使用授权。。